The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
& good luck amigos
It would be surprising if NICE didn’t recommend that the PSE test be used for screening men at risk from Prostate cancer. So it’s just a question of when IMHO and if / when that happens we will see more focus on their other available tests.
Good news today as regulators have approved a novel treatment for sickle cell disease and beta thalassemia which is the first to be licensed using the gene-editing tool known as Crispr. The results have been described as a potential cure!
Let’s hope the same phrase can be applied to AVA6000 in STS
I did notice an article in the Telegraph newspaper about about MHRA reforms.
"Although applications should be assessed within 30 days, the average wait hit four months earlier this year following a surge of applications. In an average year, the MHRA normally approves around 750 new trials per year. Since July, it has approved 2,200, wiping out a backlog of almost 1,000."
https://www.telegraph.co.uk/news/2023/11/11/life-saving-drug-trials-go-ahead-faster-uk-brexit/
Maybe those reforms will help speeds things up? 🤔
I messaged my local NHS surgery to ask if the PSE test was available (I’m in the age range where it’s recommended I get checked). My GP replied that as the sample size was quite small it was yet being offered and the regulatory authorities are awaiting for the results on a larger sample size before the test is released on the NHS. So it seems to be just a question when and how long that might take now? Especially as he seemed to indicate he’d favour being able to offer it as he added that unfortunately a prostate examination and a PSA test are still the current modes of diagnosing Prostate cancer for now.
I also think it’s interesting that the percentage they bought is just below what it would take for them to have to make an offer?
In the RNS released in May - ‘Avani now owns 29.86 per cent. of the existing Ordinary Shares in the Company (the "Ordinary Shares"). The transaction was undertaken on 10 May 2023 at a price of 18p per share (the "Transaction"). The Transaction was conducted off-market and will settle on 12 May 2023’.
18p is a lot higher than my average so I’m still holding on to my shares as Avani would have more insight into the company than I have.
His specific focus will be to grow sales in the US market, where he has considerable experience of launching products. Excellent appointment and great to see them focusing on this sizeable market.
Just added another 5000 myself 😁
Bella nice link to the different types of peer reviews. Thanks.
I think they might publish the data and go for a post published peer or open review.
Or leek?
Not the best follow up RNS but a good opportunity to buy on the dip
Personally I tie it in with the promise to release the P1a data as a way today out AVACTA’s stall and say to big Pharma what are you interested in?
Anyone care to speculate what was meant by big Al by we are entering the commercialisation phase?
Hostile takeover? 🤔
Cando They might be shifting themselves! 😂
There are rules around making statements via RNS that mean a company can be prosecuted if they make a misleading statement designed to manipulate the company share price.
I’ve added a few more below 6p. GLA
I’m in at 6p.
Is there anything that would stop the offeree buying on the open market at these prices?
I’m not sure if the repeated trade sizes mean anything Newuncle. On one of my other holdings where there seems very few trades (Alpha) there have been six trades for 777 shares at a time followed by one for 3777. If it was 666 I might feel differently! 😜
Notrex it would have been more concerning if she had resigned before the results as she would have to sign them off. I just hope her departure isn’t related to poor sales figures for Salistck? As I’d expect to see an update on the sales of Salistick given it’s been on sale for six months now, (it was launched in 400 Superdrug stores and online, via Amazon and on the Abingdon Simply Test website in June 2023, followed by its roll-out in 298 Tesco stores and Tesco online in August 2023). They should know how well it is being sold by now? & if good then why not let let us know? - not deramping here as I’m invested and think the current price is still a very good entry point although slightly higher than my average.